## iTRACK ${ }^{\text {m }}$ CASE STUDY MODERATE GLAUCOMA

# Pseudophakic uncontrolled glaucoma with prior SLT and microtrabecular bypass surgery. 

David Lubeck, MD, Arbor Eye Care, Chicago, USA.

## PATIENT ASSESSMENT

1. 75-year-old Caucasian female
2. Bilateral POAG with IOP $31 / 30 \mathrm{mmHg}$
3. Uncontrolled on 3 medications

## TREATMENT DECISION

1. Lower IOP and eliminate the need for topical medications via iTrack ${ }^{\text {m }}$ canal-based glaucoma surgery as a standalone procedure

## TREATMENT

1. Trabeculotomy was made beyond one end of the iStent and cannulation undertaken in the opposite direction, approx. $345^{\circ}$
2. Tobramycin was prescribed for 1 week, and prednisolone acetate for 3 weeks

## PATIENT OUTCOMES

1. Postop mean IOP 14.0 mmHg
2. Elimination of medications
3. Complete resolution of OSD symptoms
4. iTrack ${ }^{\text {TM }}$ performed without disruption of previously placed stent (See Figure 1)

| Baseline Findings |  |
| :---: | :---: |
| POH | - POAG OU diagnosed in 2008 <br> - Underwent SLT OU in 2012 <br> - Underwent iStent combined with cataract surgery and toric IOL placement OU in 2014 |
| BCVA | - 20/20-2 OU |
| SLE | - Mild conjunctival injection with papillary reaction OU <br> - Moderate punctate keratopathy OU <br> - Quiet anterior chamber OU <br> - Well-positioned posterior chamber IOL OU |
| IOP | - 20 mmHg OD <br> - 19 mmHg OS |
| Pachymetry | - 576/581 microns |
| Gonioscopy | - Grade 4 all quadrants with wellpositioned iStent nasally OU |
| DFE | - Cup-to-disc ratio 0.7 OU <br> - Macula, vessels, and periphery normal OU |
| HVF | - Full OU |
| OCT | - Nerve fiber layer thinning temporal OU |

Figure 1: iTrack ${ }^{\text {m" }}$ circumnavigating Schlemm's canal

| Treatment History |  |  |
| :---: | :---: | :---: |
| 2008 | Medications: <br> 1. Latanoprost (Xalatan; Pfizer) qHS <br> 2. Brinzolamide (Azopt; Alcon) BID <br> 3. Timolol (Timoptic Ocudose) qD | 1. Inadequate IOP control <br> 2. IOP returned to $30 / 25 \mathrm{mmHg}$ |
| 2012 | SLT, both eyes | 1. IOP within therapeutic range |
| 2014 | Microtrabecular bypass surgery (iStent) in conjunction with cataract surgery (toric IOL placement) | 1. IOP reduction of $8-9 \mathrm{mmHg}$ to within therapeutic range <br> 2. Continuation of all three topical medications to maintain IOP |
| 2014 | Artificial lubricants, punctal plugs, cyclosporin (Restasis; Allergan) and then serum tears | 1. IOP ranged from $17-22 \mathrm{mmHg}$ <br> 2. Persistent conjunctival inflammation and punctate keratopathy |
| 2014 | Tapered off medications to manage OSD | 1. Significant improvement in the surface dryness and inflammation <br> 2. IOP elevation to $29 / 26 \mathrm{mmHg}$ |
| 2017 | iTrack ${ }^{\text {m" }}$ performed as standalone MIGS procedure | 1. IOP within therapeutic range at 14 mmHg <br> 2. Elimination of medications <br> 3. Resolution of OSD |

© 2020, Nova Eye Medical Ltd.
iTrack ${ }^{\text {TM }}$ is a trademark of Nova Eye Medical Ltd. E\&OE. Patents pending and/or granted. iTrack ${ }^{\text {TM }}$ has a CE Mark (Conformité Européenne) and US Food and Drug Administration (FDA) 510(k) \# K080067 for the treatment of open-angle glaucoma.

CONTRAINDICATIONS: The iTrack ${ }^{\text {TM }}$ canaloplasty microcatheter is not intended to be used for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in eyes of patients with the following conditions: neovascular glaucoma; angle closure glaucoma; and, previous surgery with resultant scarring of Schlemm's canal.

ADVERSE EVENTS: Possible adverse events with the use of the iTrack ${ }^{\text {TM }}$ canaloplasty microcatheter include, but are not limited to: hyphema, elevated IOP, Descemet's membrane detachment, shallow or at anterior chamber, hypotony, trabecular meshwork rupture, choroidal effusion, Peripheral Anterior Synechiae (PAS) and iris prolapse.

WARNINGS: The iTrack ${ }^{\text {TM }}$ canaloplasty microcatheter is intended for one time use only. DO NOT re-sterilize and/or reuse, as this can compromise device performance and increase the risk of cross contamination due to inappropriate reprocessing.
PRECAUTIONS: The iTrack ${ }^{\text {TM }}$ canaloplasty microcatheter should be used only by physicians trained in ophthalmic surgery. Knowledge of surgical techniques, proper use of the surgical instruments, and post-operative patient management are considerations essential to a successful outcome.

